http://dx.doi.org/10.1016/j.clinthera.2014.09.008


http://dx.doi.org/10.1016/j.clinthera.2014.09.007

Cohen JP. Patient access to orphan drugs faces new set of challenges. *Formulary*. Online publish date: September 15, 2014. [RS 3433]


Kaitin KI, editor. Patients face new challenges accessing a growing number of orphan drugs. Tufts Center for the Study of Drug Development Impact Report. 2014 Jul/Aug;16(4)** [RS 3428]


http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=845307&pageID=1&sk=&date=

http://dx.doi.org/10.1016/j.clinthera.2014.05.004


Getz KA. Q&A with Jean Burns: Insights from a study volunteer. Applied Clinical Trials Online. Online publish date: May 28, 2014. [RS 3422]

Lamberti MJ, Getz KA, Naik P, Costello M. Clinical supply capabilities, practices, and perceptions among investigative sites. Applied Clinical Trials Online. Online publish date: May 12, 2014. [RS 3421]

http://dx.doi.org/10.3390/ijerph110505069

**This publication is for sale at our website http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1002/9781118783344.ch1


Getz KA. Coming to terms with interrupted drug development programs. *Applied Clinical Trials. Online publish date: Apr 1, 2014.* [RS 3417b]

http://dx.doi.org/10.1038/nrd4325

http://dx.doi.org/10.1038/clpt.2014.14


http://www.manhattan-institute.org/html/fda_07.htm#.U1_t61dUinw


http://csdd.tufts.edu/reports/ebooks

**This publication is for sale at our website  http://csdd.tufts.edu/reports**

http://dx.doi.org/10.3390/jpm4020163

http://dx.doi.org/10.1177/2168479014525957


Milne C-P, Davis J. The Pediatric studies initiative: after 15 years have we reached the limits of the law? *Clinical Therapeutics*. 2014;36(2):156-162. [RS 3407]
http://dx.doi.org/10.1016/j.clinthera.2013.11.007


http://dx.doi.org/10.4155/cli.13.134

http://dx.doi.org/10.1177/2168479014521419


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.3402/jmahp.v2.23513


http://dx.doi.org/10.1371/journal.pone.0084088

http://dx.doi.org/10.1038/clpt.2013.177

http://cognoscenti.wbur.org/2013/12/18/series-prescription-drug-pipeline-sidney-wolfe-kenneth-kaitin


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=828039


http://dx.doi.org/10.1038/clpt.2013.155

**This publication is for sale at our website  http://csdd.tufts.edu/reports**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://dx.doi.org/10.1517/21678707.2013.819289

http://dx.doi.org/10.1038/clpt.2013.117


http://dx.doi.org/10.1177/2168479013494386

Milne CP. On the partnering path from the US to Asia: how far, how fast for university-industry collaborations? *Pharma Focus Asia*. 2013;(18):40-45. [RS 3323]  
http://www.pharmafocusasia.com/strategy/partnering-path-us-asia.htm


**This publication is for sale at our website**  http://csdd.tufts.edu/reports
http://dx.doi.org/10.1016/j.clinthera.2013.04.004

http://www.panstanford.com/books/9789814316996.html


http://images2.advanstar.com/PixelMags/pharma-executive/digitaledition/05-2013.html#38


http://dx.doi.org/10.3111/13696998.2013.793693

Getz KA. Building clinical trial awareness for patients: why not try the pharmacist? *Pharmaceutical Executive.* Published March 1, 2013 [web document] [RS 3315]

Cohen JP. Think twice about how we let overseas use of Plan B guide us [letter to the editor]. *The Boston Globe.* April 21, 2013:K8. [RS 3314]

http://dx.doi.org/10.1377/hlthaff.2012.0707

http://dx.doi.org/10.1016/j.clinthera.2012.12.018

http://dx.doi.org/10.1016/j.cct.2013.02.007

http://dx.doi.org/10.1177/2168479013478953


Getz KA, Stergiopoulos S, Marlborough M, Whitehill J, Curran M, Kaitin KI. Quantifying the magnitude and cost of collecting extraneous protocol data. *American Journal of Therapeutics*. 2013. [Published Ahead-of-Print; Last Updated: April 9, 2013] [RS 3307]
http://dx.doi.org/10.1097/MJT.0b013e31826fc4aa


http://dx.doi.org/10.1097/MJT.0b013e318269198f

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

Kaitin KI, editor. 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. *Tufts Center for the Study of Drug Development Impact Report*. 2013 Jan/Feb;15(1)** [RS 3302]

http://dx.doi.org/10.1177/2168479012469947


http://dx.doi.org/10.1016/j.anai.2012.11.014

http://dx.doi.org/10.1634/theoncologist.2012-0235


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1586/ecp.12.44

http://dx.doi.org/10.1007/s12031-012-9803-8


http://dx.doi.org/10.1097/MJT.0b013e318262316f

http://www.topra.org/regulatory-rapporteur-oct-2012

http://dx.doi.org/10.1007/BF03262374


Kaitin KI. Translational research and the evolving landscape for biomedical innovation. *Journal of Investigative Medicine.* 2012;60(7):995-998 [RS 3228]  
http://dx.doi.org/10.231/JIM.0b013e318268694f

http://dx.doi.org/10.1586/erp.12.25


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://dx.doi.org/10.1038/clpt.2012.87


http://www.pharmafocusasia.com/research_development/application-Biopharmaceutics-Classification-System-Drug-Development.htm


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Feature+Article/Outsourcing-Landscape/ArticleStandard/Article/detail/772232

http://dx.doi.org/10.1016/j.drudis.2012.04.006

Reichert JM. Marketed therapeutic antibodies compendium. mAbs. 2012;4(3):413-415 [RS 3215b]  
http://dx.doi.org/10.4161/mabs.19931


http://dx.doi.org/10.1586/ecp.12.7

http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=763940&sk=&date=&&pageID=1

http://dx.doi.org/10.1136/medethics-2011-100411

http://dx.doi.org/10.1016/j.nbt.2012.02.001

http://dx.doi.org/10.4161/mabs.4.2.18812

**This publication is for sale at our website   http://csdd.tufts.edu/reports


**This publication is for sale at our website  http://csdd.tufts.edu/reports
Kaitin KI. Creating innovation nodes to meet unmet medical needs. *Pharmaceutical Technology*. 2011;35(12):27 [RS 3132]

Getz KA. Transforming legacy R&D through open innovation. *ACRP Monitor*. 2011;25(7):17-21 [RS 3131b]

http://dx.doi.org/10.1089/pop.2011.0020


http://dx.doi.org/10.1016/j.jval.2011.05.004

http://dx.doi.org/10.4161/mabs.3.5.17334


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
Milne C-P. The case for pediatric exclusivity. *Pharmaceutical Technology*. 2011;35(9):38 [RS 3126]

http://dx.doi.org/10.1586/ecp.11.45

http://dx.doi.org/10.1089/pme.11.51


http://dx.doi.org/10.1038/scientificamerican0811-16

http://dx.doi.org/10.4161/mabs.3.4.16589


http://dx.doi.org/10.1177/009286151104500403

http://dx.doi.org/10.1177/009286151104500406


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
Kaitin KI. 21st Century innovation: academic-industry partnerships are increasingly important in biopharmaceutical innovation. *Pharmaceutical Technology*. 2011;35(6):32 [RS 3119]
http://pharmtech.findpharma.com/pharmtech/article/articleDetail.jsp?id=724982&sk=&date=&&pageID=1

http://www.emaud.org/Doc/Market_Access_Newsletter_EMAUD_June%202011.pdf


Reichert JM. The amazing, multipurpose antibody. *mAbs*. 2011;3(3):221-222. [RS 3116b]
http://dx.doi.org/10.4161/mabs.3.3.15625

http://dx.doi.org/10.2217/pme.11.38

http://dx.doi.org/10.1177/009286151104500316

http://dx.doi.org/10.1177/009286151104500307

http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=719542&sk=9270beba3a37ef7e37f3fa5477eea1cf9%22


Kaitin KI, editor. New or modified indications for existing drugs have steadily increased in the U.S. *Tufts Center for the Study of Drug Development Impact Report*. 2011 Mar/Apr;13(2)** [RS 3111]
http://dx.doi.org/10.4161/mabs.3.2.14788

http://dx.doi.org/10.1177/009286151104500203

Getz KA. Low hanging fruit in the fight against inefficiency. Applied Clinical Trials. 2011;20(3):30-32 [RS 3109]
http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Articles/Low-Hanging-Fruit-in-the-Fight-Against-Inefficiency/ArticleStandard/Article/detail/711311?contextCategoryId=37194

http://dx.doi.org/10.1038/clpt.2010.286

Stergiopoulos S, Soenen M, Getz KA. Honing reforms from clinical development. Pharmaceutical Executive. Published February 1, 2011 [web document]. [RS 3107]

Getz KA. The ultimate act of appreciation of study volunteers. Focus. 2011;3:8-12 [RS 3106b]

http://dx.doi.org/10.4161/mabs.3.1.13895


**This publication is for sale at our website http://csdd.tufts.edu/reports
http://dx.doi.org/10.1177/009286151104500106

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=703033&sk=&date=&pageID=2


http://dx.doi.org/10.4161/mabs.2.6.13603

http://dx.doi.org/10.1038/clpt.2010.167

http://dx.doi.org/10.1038/nbt1110-1160

Getz KA. Hurry up and wait, pharma puts the brakes on strategic outsourcing partnering. *Inside Outsourcing*. 2010 Nov;10-16 [RS 3026b]
http://www.nxtbook.com/nxtbooks/advanstar/insideoutsourcing_201011/#/12

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=693552


**This publication is for sale at our website  http://csdd.tufts.edu/reports**

Getz KA. Providing results to volunteers. *Applied Clinical Trials.* 2010;19(10):52-59 [RS 3023b]

http://license.icopyright.net/rights/tag.act?tag=3.7442%3ficx_id=686210

http://dx.doi.org/10.1038/nrd3229

http://dx.doi.org/10.1002/hec.1538


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=673673&sk=&date=&pageID=3


RS 3016d Getz KA. Engaging pharmacists in research education. *Applied Clinical Trials.* 2010;19(7):30-32
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=678141

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1038/clpt.2010.86

http://dx.doi.org/10.4161/mabs.12369

http://dx.doi.org/10.1093/jnci/djq246


http://dx.doi.org/10.1371/journal.pone.0010610


Getz K. FIPNet: Pharma’s new, sexy, but not yet ready for print-time model. *Applied Clinical Trials.* 2009;Suppl:10-12,14,16

Kaitin KI. The landscape for pharmaceutical innovation: Drivers of cost-effective clinical research. *Pharmaceutical Outsourcing.* 2010;11(3):28,30,32
Author manuscript; available in PMC 2011 August 4. PMCID: PMC3150117

Getz KA. Conversations with study volunteers. *Applied Clinical Trials.* 2010;19(5):32-34
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/CRO%2FSponsor/Conversations-With-Study-Volunteers/ArticleStandard/Article/detail/668513


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 3009  Getz KA. Sizing up the clinical research market. *Applied Clinical Trials*. 2010;19(3):32-34  
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=660749

RS 3008  Getz KA. With clinical data, less is more. *Applied Clinical Trials*. 2010;19(1):28-30  
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/CRO%2FSponsor/With-Clinical-Data-Less-is-More/ArticleStandard/Article/detail/652123

http://dx.doi.org/10.1093/protein/gzq018

RS 3007b  Getz KA. Understanding clinical trials: Appreciating medical heroes. *Media Planet*. 2010 Apr  


http://dx.doi.org/10.4161/mabs.2.2.11320

http://dx.doi.org/10.1097/MJT.0b013e3181ca7f10


http://dx.doi.org/10.1038/clpt.2009.293


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.4161/mabs.2.1.10628

Reichert JM. Antibodies to watch in 2010. *MAbs.* 2010;2(1):84-100;
http://dx.doi.org/10.4161/mabs.2.1.10786


Getz KA, Vogel JR. Successful outsourcing: tracking global CRO usage. *Applied Clinical Trials Online.* 2009 Aug 17

http://dx.doi.org/10.2217/pme.09.40


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1017/S0266462309090072


http://dx.doi.org/10.1126/scitranslmed.3000222

http://dx.doi.org/10.1007/BF03256155


http://dx.doi.org/10.4161/mabs.1.6.10059


RS2921b Getz KA. Into the aftermath of M&A. *Applied Clinical Trials*. 2009;18(9)  


http://dx.doi.org/10.4161/mabs.1.5.9675

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.4161/mabs.1.4.9031


http://dx.doi.org/10.1177/009286150904300415


http://www.fdsli.org/resources/resources-order-box-detail-view/off-label-use-reimbursement

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=609455


http://dx.doi.org/10.4161/mabs.1.4.9076


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.4161/mabs.1.1.7645


http://dx.doi.org/10.4161/mabs.1.3.8590


http://www.pharmexec.com/pharmexec/Sales+Articles/Make-a-Match/ArticleStandard/Article/detail/592061

http://dx.doi.org/10.1038/nbt0409-331

http://dx.doi.org/10.1177/009286150904300212

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=586863

http://dx.doi.org/10.1136/jme.2008.024711

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
RS 2905  Kaitin KI, editor. 75% of U.S. health plans reimburse off-label uses of prescription drugs. Tufts Center for the Study of Drug Development Impact Report. 2009 Mar/Apr;11(2)**


RS 2904c  Reichert JM. Letter from the editor. MAbs. 2009 Mar/Apr;1(2):91-92; http://dx.doi.org/10.4161/mabs.1.2.7946


**This publication is for sale at our website http://csdd.tufts.edu/reports**


Getz KA. Should physicians enroll their own patients into clinical trials? *ACRP Monitor.* 2008 Dec;22(7):34-38


Reichert JM, Rochon SL, Zhang BD. A decade of the Fast Track programme. *Nature Reviews Drug Discovery.* 2008;7(11):885-6 [http://dx.doi.org/10.1038/nrd2733](http://dx.doi.org/10.1038/nrd2733)


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Getz KA. Getting to the heart of public distrust. *Applied Clinical Trials*. 2008; 17(9):38-42


[http://www.contractpharma.com/articles/2008/06/clinical-research-outsourcing](http://www.contractpharma.com/articles/2008/06/clinical-research-outsourcing)

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 2821 Zycher B, DiMasi JA, Milne C-P. *The truth about drug innovation: thirty-five summary case histories on private sector contributions to pharmaceutical science.* Manhattan Institute Center for Medical Progress. 2008;(6).
http://www.manhattan-institute.org/html/mpr_06.htm

RS 2820 Getz KA. First things first: patient recruitment. *Scrip.* 2008;3371(6)

http://dx.doi.org/10.1002/9780471462422.eoct336


http://dx.doi.org/10.1215/03616878-2007-054

http://dx.doi.org/10.1215/03616878-2007-063


RS 2815 Getz KA. Beyond outsourcing (interview by Jenefer Trevena). *Scrip Supplement Contract Research Update.* 2008;Apr;4:5-6


http://dx.doi.org/10.1586/14737167.8.2.133


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 2809  Getz KA. In search of efficiency between trial phases. *Applied Clinical Trials*. 2008;17(3):35-38
http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Clinical+Trial+Insights/In-Search-of-Efficiency-Between-Trial-Phases/ArticleStandard/Article/detail/500433?contextCategoryId=37194

http://dx.doi.org/10.1097/MJT.0b013e31815fa75a


http://dx.doi.org/10.1177/009286150804200108

http://dx.doi.org/10.1016/j.drudis.2007.09.003

http://dx.doi.org/10.1097/MJT.0b013e31815f9e52


http://dx.doi.org/10.1038/sj.clpt.6100462

**This publication is for sale at our website  http://csdd.tufts.edu/reports**


RS 2728 DiMasi JA, Grabowski HG. Should the patent system for new medicines be abolished? *Clinical Pharmacology & Therapeutics*. 2007;82(5):488-90 [http://dx.doi.org/10.1038/sj.clpt.6100393](http://dx.doi.org/10.1038/sj.clpt.6100393)


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://dx.doi.org/10.1007/s10198-007-0055-4

http://dx.doi.org/10.1002/mde.1360

http://dx.doi.org/10.1002/mde.1341

RS 2717  Getz KA. CRA: jack of all trades. *Applied Clinical Trials*. 2007;16(7):36-38  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=439804


http://dx.doi.org/10.1097/MJT.0b013e31809fca83

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=424918

http://dx.doi.org/10.1038/nrd2241


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
Getz KA, Sergeant E, Kremidas J. Mission possible: rebranding clinical research. *Applied Clinical Trials.* 2007;16(4):35-6,8

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=416536


http://www.jstor.org/pss/30033224

Getz K, Wenger J. High times for the CRO heavyweights. *Scrip supplements.* 2007 Mar;5-6


http://dx.doi.org/10.2165/00124363-200620050-00003

Getz KA. Drowning in the sea of regulatory compliance. *Applied Clinical Trials.* 2007;16(2):32-34

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=401621


http://dx.doi.org/10.2165/00063030-200721010-00001


http://dx.doi.org/10.1200/JCO.2006.09.0803


**This publication is for sale at our website  http://csdd.tufts.edu/reports**

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=392454


RS 2624b Cohen J Cairns C Paquette C Faden L. Comparing patient access to pharmaceuticals in the UK and US. *Applied Health Economics and Health Policy*. 2006;5(3):177-87  
http://dx.doi.org/10.2165/00148365-200605030-00004

http://dx.doi.org/10.2165/00148365-200605040-00009

http://dx.doi.org/10.1111/j.1365-2710.2006.00777.x

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=382875


http://dx.doi.org/10.2165/00019053-200624002-00013

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=370345

**This publication is for sale at our website  http://csdd.tufts.edu/reports**

http://dx.doi.org/10.1097/00001888-200608000-00006

http://dx.doi.org/10.1016/j.tibtech.2006.05.003


http://harpers.org/archive/2006/07/letters-766/

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=334568

http://dx.doi.org/10.1377/hlthaff.25.2.461

http://dx.doi.org/10.1001/jama.295.23.2723-a


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


RS 2606  Getz KA. Forgotten voices in the transparency debate: online trial registries alone will not succeed at rebuilding public confidence. *Applied Clinical Trials*. 2006;15(4):42-44
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=316473


http://dx.doi.org/10.1038/nrd1987


http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=282477

RS 2601  Getz KA. The imperative to support site adoption of EDC. *Applied Clinical Trials*. 2006;15(1):38-40
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=283027


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=261633

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 2517  Getz KA.  Have we pushed our PIs too far?  *Applied Clinical Trials*.  
2005;14(9):34-36  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=176904&pageID=1

RS 2516  Getz KA.  The public: a critical initiative partner.  *Applied Clinical Trials*.  
2005;14(8):50  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172272

RS 2515  Milne C-P  Kaitin KI.  Down the critical path: who should lead?  *Applied Clinical Trials*.  
2005;14(8):56  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172279

2005 May-Jun;27(3):1-7  
http://dx.doi.org/10.2307/3564071

2005 Apr 28;352(17):1825-7  
http://dx.doi.org/10.1056/NEJM200504283521723

RS 2512  DiMasi JA  Hansen RW  Grabowski HG.  Reply: setting the record straight on setting the record straight: response to the Light and Warburton rejoinder.  *Journal of Health Economics*.  
2005 Sep;24(5):1049-53  

2005 Sep;24(5):1034-44  

RS 2510  Kaitin KI, editor.  Longer clinical times are extending time to market for new drugs in U.S.  *Tufts Center for the Study of Drug Development Impact Report*.  
2005 Nov/Dec;7(6)**

RS 2509  Reichert JM  Rosensweig CJ  Faden LB  Dewitz MC.  Monoclonal antibody successes in the clinic.  *Nature Biotechnology*.  
2005;23(9):1073-8  
http://dx.doi.org/10.1038/nbt0905-1073

**This publication is for sale at our website  http://csdd.tufts.edu/reports**

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=149965


http://dx.doi.org/10.1017/S0266462304001291

RS 2423  Milne C-P. Harbingers, or harvesters of change?  *European Pharmaceutical Review Supplement (Outsourcing).* 2004 Winter:12-17

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://dx.doi.org/10.1136/bmj.330.7481.39


http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=12516


http://dx.doi.org/10.1038/nbt1204-1513


http://dx.doi.org/10.1177/009286150403800301


**This publication is for sale at our website  http://csdd.tufts.edu/reports**

http://dx.doi.org/10.1056/NEJM200405203502127

http://dx.doi.org/10.1177/009286150303700401


http://dx.doi.org/10.1038/nrd1386


http://dx.doi.org/10.1177/00928615040380105


http://dx.doi.org/10.1016/S1359-6446(04)03025-9

**This publication is for sale at our website  http://csdd.tufts.edu/reports


http://dx.doi.org/10.1177/009286150303700403

http://dx.doi.org/10.1076/jmep.28.3.327.14586

http://dx.doi.org/10.1177/009286150303700310

http://dx.doi.org/10.1345/aph.1D110

http://dx.doi.org/10.1097/00045391-200309000-00010


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1038/nrd1178


http://dx.doi.org/10.2190/XD07-L5KF-YBFE-YB52


http://dx.doi.org/10.1016/S0167-6296(02)00126-1

RS 2301  Kaitin KI, editor. Increased pressure on drug industry is leading to greater focus on Japan. *Tufts Center for the Study of Drug Development Impact Report*. 2003 Jan/Feb;5(1)**


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


http://dx.doi.org/10.2165/00019053-200220003-00011


RS 2218  Kaitin KI, editor. Approval times for new drugs fell by more than a year during PDUFA. *Tufts Center for the Study of Drug Development Impact Report.* 2002 Nov/Dec;4(6)**

http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=36729


http://dx.doi.org/10.1038/nbt0802-780


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1038/nbt0702-659

RS 2211  Cohen J  Chee J. Pharmacy benefit managers’ role in facilitating Medicare beneficiary access to pharmaceutical care. *Disease Management & Health Outcomes*. 2002;10(4):221-7
http://dx.doi.org/10.1177/009286150103500228


RS 2203  Reichert JM  Therapeutic monoclonal antibodies: trends in development and approval in the US. *Current Opinion in Molecular Therapeutics*. 2002;4(2):110-8


**This publication is for sale at our website http://csdd.tufts.edu/reports**


RS 2123 Kaitin KI. El papel de la investigación básica. [editorial]. (Original title: The quest for cures -- the role of the research-based drug industry) *La Vanguardia* (Barcelona). 2001 18 Mar*


  http://dx.doi.org/10.1038/nbt0901-819

  http://dx.doi.org/10.2165/00019053-200119070-00004


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1177/009286150103500228


http://dx.doi.org/10.1177/009286150103500203


http://dx.doi.org/10.1067/mcp.2001.115446

http://dx.doi.org/10.1067/mcp.2001.115132


http://dx.doi.org/10.1177/009286150103500108

http://dx.doi.org/10.1177/009286150103500109


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
RS 2102 Kaitin KI, editor. FDA’s fast track program results in 62% approval rate after first 3 years. Tufts Center for the Study of Drug Development Impact Report. 2001 Jan/Feb;3(1)**


RS 2023 Cross-functional team focus on marketing is key to project success. Tufts Center for the Study of Drug Development Impact Report. 2000 Dec;2(9)


RS 2018 Kaitin KI. Don’t turn back the clock on drug regulatory reform. Tufts Center for the Study of Drug Development Impact Editorial. 2000 Sep;2(7) http://dx.doi.org/10.1097/01.COT.0000293239.37468.b0

**This publication is for sale at our website  http://csdd.tufts.edu/reports**

http://dx.doi.org/10.1016/S0167-7799(00)01473-6


http://dx.doi.org/10.1177/009286150003400303

http://www.acnp.org/g4/GN401000182/Default.htm

http://dx.doi.org/10.1177/009286150003400304


RS 2008  Drug firms embrace pediatric study program during first 2 years of FDAMA. *Tufts Center for the Study of Drug Development Impact Report.* 2000 Apr;2(3)

http://dx.doi.org/10.1001/jama.283.15.2013


European approval of new biotech drugs outpaces US approval. Tufts Center for the Study of Drug Development Impact Report. 2000 Mar;2(2)


Effective data use drives portfolio management and global strategies. Tufts Center for the Study of Drug Development Impact Report. 2000 Jan;2(1)


Planning, independence, feedback keep global R&D projects on track. Tufts Center for the Study of Drug Development Impact Report. 1999 Sep;1(3)

Clinical development times for new drugs drop 18%, reversing 12-yr trend. Tufts Center for the Study of Drug Development Impact Report.1999 Jul;1(2)


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website http://csdd.tufts.edu/reports**


[http://dx.doi.org/10.1016/S0009-9236(97)90026-6](http://dx.doi.org/10.1016/S0009-9236(97)90026-6)


[http://dx.doi.org/10.2165/00019053-199712030-00004](http://dx.doi.org/10.2165/00019053-199712030-00004)

[http://dx.doi.org/10.1177/009286159703100319](http://dx.doi.org/10.1177/009286159703100319)

RS 9725  Lasagna L  Weintraub M, editors.  *Year book of drug therapy 1997.*  St. Louis: Mosby;1997*

[http://dx.doi.org/10.3109/10601339709019438](http://dx.doi.org/10.3109/10601339709019438)


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1097/00045391-199705000-00002


http://dx.doi.org/10.1097/00045391-199701000-00010

http://dx.doi.org/10.1038/nbt0297-130

RS 9715  Kaitin KI. FDA reform: setting the stage for efforts to reform the agency. *Drug Information Journal.* 1997;31(1):27-33  
http://dx.doi.org/10.1177/009286159703100105

RS 9714  Lasagna L DiMasi JA. Let’s speed up the approval of new indications for old drugs. *Medical Marketing & Media* 1996;31(12):88-9

http://dx.doi.org/10.1016/S0009-9236(96)90209-X

http://dx.doi.org/10.1177/009286159603000416

**This publication is for sale at our website**  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 9625  DiMasi JA. *Written testimony*. House Subcommittee on Human Resources and Intergovernmental Affairs, Committee on Government Reform and Oversight, U.S. House of Representatives. September 12, 1996


RS 9623  Kaitin KI. *Statement*. Hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives. The Need for FDA Reform, February 27, 1996. 104th Congress 2d Session:81-7, 100-1


http://archive.wilsonquarterly.com/essays/research-dilemma


http://dx.doi.org/10.1177/009286159603000103


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


[http://dx.doi.org/10.1097/00045391-199609000-00008](http://dx.doi.org/10.1097/00045391-199609000-00008)


[http://dx.doi.org/10.1177/009286159603000201](http://dx.doi.org/10.1177/009286159603000201)


[http://dx.doi.org/10.2165/00019053-199609020-00004](http://dx.doi.org/10.2165/00019053-199609020-00004)

[http://dx.doi.org/10.1097/00004714-199512000-00001](http://dx.doi.org/10.1097/00004714-199512000-00001)

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1097/00045391-199509000-00023

http://dx.doi.org/10.1016/0009-2366(95)90240-6

http://dx.doi.org/10.1177/009286159502900227

RS 9506  Shulman SR Seibring M Manocchia M. *Letter to Hon. Judd Gregg, U.S. Senate.* Hearing before the Subcommittee on Aging of the Committee on Labor and Human Resources, United States Senate, July 13, 1995 104th Congress 1st Session:47-8


http://dx.doi.org/10.1097/00004714-199504000-00002


http://dx.doi.org/10.1016/0009-2366(95)90066-7

http://dx.doi.org/10.1016/0009-2366(95)90078-0

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://dx.doi.org/10.1080/758519309

http://dx.doi.org/10.1177/009286159502900202

PS 9596  Brown JS  DiMasi JA  Gosse ME  Manocchia M  Kaitin KI  Shulman SR. *Incentives for the development of drugs for AIDS and other life-threatening illnesses: points to consider.* For the Public/Private Issues and Development Subcommittees of the National Task Force on AIDS Drug Development meeting, April 25, 1995

http://dx.doi.org/10.2165/00019053-199507020-00007

RS 9594  Bloom BR. The United States needs a national vaccine authority. *Science.* 1994 Sep 2;265(5177):1378-80  
http://dx.doi.org/10.1126/science.8073275

http://www.acnp.org/g4/GN401000182/Default.htm

http://www.fdlj.org/mobile/resources-detail-view/?friendlyname=the-drug-export-amendments-act-of-1986-is-it-all-it-was-intended-to-be

**This publication is for sale at our website**  
http://csdd.tufts.edu/reports
http://dx.doi.org/10.1215/03616878-19-4-922


http://dx.doi.org/10.1002/j.1552-4604.1994.tb02044.x

RS 9496  Lasagna L. *Statement of Louis Lasagna, M.D., Dean, Tufts Sackler School of Graduate Biomedical Sciences at the National Institutes of Health CRADA forum, July 21, 1994*. Washington DC: New England Biomedical Research Coalition, 1994


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 9485  Inman WHW. Drug Safety Research Unit, University of Southampton. *PEM News.* 1993 Nov;(8)


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1215/03616878-17-4-847

http://dx.doi.org/10.1002/j.1552-4604.1993.tb04680.x

http://dx.doi.org/10.1038/nbt0293-168


http://dx.doi.org/10.7326/0003-4819-115-4-315

http://dx.doi.org/10.1177/009286159202600305

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1177/009286159202600105

http://dx.doi.org/10.1038/clpt.1991.97

http://dx.doi.org/10.1038/nbt0592-521


RS 9266  Scoville B. Shifting the burden: restructuring the drug review process. *Journal of Clinical Pharmacology and Therapeutics.* 1991;49(3):229-33  
http://dx.doi.org/10.1038/clpt.1991.21


http://dx.doi.org/10.1038/clpt.1991.172

http://dx.doi.org/10.1056/NEJM199108013250513


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://dx.doi.org/10.1016/0167-6296(91)90001-4


http://dx.doi.org/10.1002/j.1552-4604.1991.tb04963.x


http://dx.doi.org/10.1002/j.1552-4604.1991.tb03694.x

http://dx.doi.org/10.1002/sim.4780090302


http://dx.doi.org/10.1002/j.1552-4604.1991.tb01882.x


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

RS 9054  Shulman SR.  La legislazione sulla responsabilità di produzione. Informazioni Stampa Interesse Sanitario (Rome) 1990 Apr 9;#15:27-8

RS 9053  Lasagna L.  Le attività del Centro per lo Studio dello Sviluppo dei Farmaci. Informazioni Stampa Interesse Sanitario (Rome) 1990 Apr 9;#15:26

RS 9052  Inman WHW.  Drug Safety Research Unit, University of Southampton, PEM News. 1988 Sep(5)


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://dx.doi.org/10.2105/AJPH.79.11.1565

http://dx.doi.org/10.1177/009286158802200104

http://dx.doi.org/10.1002/j.1552-4604.1989.tb03249.x

http://dx.doi.org/10.1038/clpt.1989.118


http://dx.doi.org/10.1002/j.1552-4604.1989.tb03402.x


http://dx.doi.org/10.1038/clpt.1989.116


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 8934  Grabowski HG. Medicaid patients' access to new drugs. *Health Affairs* 1989;7:102-14  
http://dx.doi.org/10.1377/hlthaff.7.5.102

http://dx.doi.org/10.1001/jama.1988.03410150098038

http://dx.doi.org/10.1016/0273-2300(88)90007-4

http://dx.doi.org/10.1016/0273-2300(88)90013-X

RS 8930  Inman WHW. Drug Safety Research Unit, University of Southampton. *PEM News*. 1988 Sep;(5)


RS 8830  Shulman SR. Drug refusal policy must include legal definition of competence. *Hospital Formulary*. 1988 Jan;23:79

RS 8829  DiMasi JA. The notion of "acceptable risk": comment. *Journal of Clinical Epidemiology*. 1988;41(9):939-41  
http://dx.doi.org/10.1016/0895-4356(88)90111-4


**This publication is for sale at our website**  http://csdd.tufts.edu/reports

http://dx.doi.org/10.1002/j.1552-4604.1988.tb05747.x

RS 8824  Wittes RE. Antineoplastic agents and FDA regulations: square pegs for round holes? *Cancer Treatment Reports*. 1987;71(9):795-806


http://dx.doi.org/10.1038/clpt.1988.35

http://dx.doi.org/10.1287/mnsc.33.3.381

http://dx.doi.org/10.1002/mde.4090070404

http://dx.doi.org/10.1177/009286158702100310

http://dx.doi.org/10.1002/j.1552-4604.1987.tb03064.x

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

RS 8720  
[http://dx.doi.org/10.3109/10601338709032965](http://dx.doi.org/10.3109/10601338709032965)

RS 8719  

RS 8718  

RS 8717  
[http://dx.doi.org/10.2131/jts.12.439](http://dx.doi.org/10.2131/jts.12.439)

RS 8716  

RS 8715  

RS 8714  
[http://dx.doi.org/10.1038/clpt.1987.42](http://dx.doi.org/10.1038/clpt.1987.42)

RS 8713  
[http://dx.doi.org/10.7326/0003-4819-106-6-886](http://dx.doi.org/10.7326/0003-4819-106-6-886)

RS 8712  

PS 8711  

RS 8710  
Inman WHW. Drug Safety Research Unit, University of Southampton, *PEM News*. 1987 Mar;(4)

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1177/009286158501900327

http://dx.doi.org/10.1038/clpt.1986.192


http://dx.doi.org/10.1002/j.1552-4604.1986.tb02950.x


http://dx.doi.org/10.1016/0273-2300(86)90006-1


http://dx.doi.org/10.1111/j.1365-2125.1987.tb03099.x

http://dx.doi.org/10.1001/jama.1986.03380180128035


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://dx.doi.org/10.1017/S0266462300003445


http://dx.doi.org/10.1080/00031305.1985.10479435


http://dx.doi.org/10.1111/j.1539-6924.1986.tb00194.x

Berry CL. Unprovable verities. *Human Toxicology*. 1985;5(3):159-60

Weintraub M, Northington F. Drugs that wouldn't die. *Journal of the American Medical Association*. 1986 May 2;255(17):2327-8

http://dx.doi.org/10.1001/jama.1986.03370170091042


http://dx.doi.org/10.1177/009286158602000105


Inman WHW. Drug Surveillance Research Unit, University of Southampton. *PEM News*. 1985 Dec;(3)


**This publication is for sale at our website**  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)
| RS 8591 | Mattison N. Sources of change affecting the U.S. pharmaceutical industry in the 1980s. *Pharmaceutical Medicine*. 1985;1:89-96* |

**This publication is for sale at our website** [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)
http://dx.doi.org/10.1038/clpt.1985.54

http://dx.doi.org/10.1002/ddr.430040402


http://dx.doi.org/10.1038/clpt.1984.224


RS 8478  Lasagna L.  *Impediments to Vaccine Research, Medicine in the Public Interest Conference, Jan 9-10, 1984.*  Boston: MIPI;1984

RS 8477  Inman WHW.  Drug Surveillance Research Unit, University of Southampton, *PEM News.* 1984 Aug;(2)

http://dx.doi.org/10.1016/0273-2300(84)90038-2

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1038/clpt.1984.78


RS 8474 Weintraub M. P&T committees and drug regulation in Norway: lessons to be learned. *Hospital Formulary.* 1984;19:347


http://dx.doi.org/10.2307/3564062


http://dx.doi.org/10.1056/NEJM198311243092105


RS 8468 Hutt PB. The importance of patent term restoration to pharmaceutical innovation: will extending patent life increase drug innovation? A search for answers. *Health Affairs.* 1982;1(2):5-24  
http://dx.doi.org/10.1377/hlthaff.1.2.6


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://dx.doi.org/10.1001/jama.1983.03330400070028


Superior Court of New Jersey, Appellate Division. Carol Ann Feldman, an infant, by her parent and guardian *ad litem* Harold Feldman, Plaintiffs - Appellants vs. Lederle Laboratories, a corporation, and American Cyanamid Co., a corporation, Defendants - Respondents. Nov 1983

Inman WHW. Drug Surveillance Research Unit, University of Southampton. *PEM News*. 1983 Aug;(1)

Covington TR. Toward a rational approach to the issue of prescribing authority for pharmacists. *Drug Intelligence and Clinical Pharmacy*. 1983;17(9):660-6

http://dx.doi.org/10.1038/clpt.1983.95

http://www.jstor.org/stable/41110241


http://dx.doi.org/10.1038/clpt.1983.73

***This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)***


RS 8358b Zbinden G Flury-Roversi M. Significance of the LD 50 test for the toxicological evaluation of chemical substances. *Archives of Toxicology*. 1981 Apr;47(2):77-99 http://dx.doi.org/10.1007/BF00332351


RS 8357b Mahler H. Essential drugs for all. *Papers presented at the Eleventh IFPMA Assembly, Washington DC, Jun 7-8, 1982:* 64-70


**This publication is for sale at our website** [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)

RS 8262  Wardell WM. Is pharmaceutical innovation declining?  Pharmaceutical Technology. 1982 Sep


RS 8260  Wardell WM  Mattison N. The assessment of medical technologies using risk-benefit, cost-benefit, and cost-effectiveness analysis. In: WMA Follow-up Committee on Development and Allocation of Medical Care Resources. Tokyo: Japan Medical Association;1982;84-98*


RS 8253b  Schweiker RS. Remarks by the Honorable Richard S. Schweiker to the National Pharmaceutical Council Symposium. June 23, 1982


**This publication is for sale at our website http://csdd.tufts.edu/reports**

  http://dx.doi.org/10.1038/clpt.1982.34

RS 8250  Wardell WM.  *A statement on pharmaceutical patent life and innovation*.  Submitted to the Subcommittee on Investigations and Oversight of the Committee on Science and Technology, U.S. House of Representatives. Feb 4, 1982


  http://dx.doi.org/10.1001/jama.1981.03310450044021


  http://dx.doi.org/10.1007/978-1-4684-4055-3


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


RS 8059  Hansen RW.  *Effects of incremental costs on pharmaceutical innovation.* (Working Paper Series No. GPB-81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

RS 8058  Hansen RW.  *The cost of regulation in the pharmaceutical industry: economic implications of three recent studies.*  (Working Paper Series No. PS 81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

RS 8057  Wardell WM.  Therapeutic drugs as an example of the regulation of health care: efficient and inefficient ways of utilizing resources.  *In: Proceeding of the World Medical Association Follow-Up Committee Meeting on Development and Allocation of Medical Care Resources.* Tokyo: Japan Medical Association, 1980:139-50*

RS 8056  Wardell WM.  Drug therapy (a response to questions on specific aspects of drug regulation).  *Private Practice.* 1980 Oct:24-31*


http://dx.doi.org/10.1002/j.1552-4604.1980.tb01660.x

RS 8051  Lasagna L.  Pharmacology's labs have moved faster than the regulators.  *Medical Tribune.* 1980 May 7;21:17


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.7326/0003-4819-92-3-419


RS 8046  Hansen RW. *Pharmaceutical development costs by therapeutic categories.* (Working Paper Series No. GPB-80-6) Rochester, NY: Graduate School of Management, University of Rochester; Mar 1980*


http://dx.doi.org/10.1007/BF01968667


**This publication is for sale at our website**  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)
http://dx.doi.org/10.1038/clpt.1980.160


PS 8032  Merrill RA. *Problems involving federal conflict of interest restrictions on members of FDA advisory committees and agency officials.* Rochester, NY: Center for the Study of Drug Development; Apr 1980


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


http://dx.doi.org/10.1021/bk-1979-0109.ch009


RS 7939  Lasagna L. Toxicological barriers to providing better drugs. Archives of Toxicology. 1979;43(1):27-33  
http://dx.doi.org/10.1007/BF00695871

RS 7938  Lasagna L. Prescription drugs: the investment with the biggest dividends. Private Practice. 1979;11(5):42-3

http://dx.doi.org/10.1002/j.1552-4604.1979.tb02464.x

**This publication is for sale at our website http://csdd.tufts.edu/reports**


RS 7926b  Lasagna L.  The diseases and drug needs of the Third World.  *Journal of Chronic Diseases*.  1979;32(6):413-4  
[http://dx.doi.org/10.1016/0021-9681(79)90101-2](http://dx.doi.org/10.1016/0021-9681(79)90101-2)

**This publication is for sale at our website**  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


PS 7816 Landau RL. What you should know about estrogens, or the perils of Pauline. Rochester, NY: Center for the Study of Drug Development; Jun 1978


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


http://dx.doi.org/10.1007/BF03284217

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1056/NEJM197702032960505


http://dx.doi.org/10.1097/00012995-197608000-00001


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**